The Mexican swine flu, a genetic chimera probably conceived in the faecal mire of an industrial pigsty, suddenly threatens to give the whole world a fever. The initial outbreaks across North America reveal an infection already travelling at higher velocity than did the last official pandemic strain, the 1968 Hong Kong flu.

Stealing the limelight from our officially appointed assassin, H5N1, this porcine virus is a threat of unknown magnitude. It seems less lethal than Sars in 2003, but as an influenza it may be more durable than Sars. Given that domesticated seasonal type-A influenzas kill as many one million people a year, even a modest increment of virulence, especially if combined with high incidence, could produce carnage equivalent to a major war.

Meanwhile, one of its first victims has been the consoling faith, long preached by the World Health Organisation, that pandemics can be contained by the rapid responses of medical bureaucracies, independent of the quality of local public health. Since the initial H5N1 deaths in Hong Kong in 1997, the WHO, with the support of most national health services, has promoted a strategy focused on the identification and isolation of a pandemic strain within its local radius of outbreak, followed by a thorough dousing of the population with antivirals and (if available) vaccine.

An army of skeptics has contested this viral counter-insurgency approach, pointing out that microbes can now fly around the world (quite literally in the case of avian flu) faster than WHO or local officials can react to the original outbreak. They also pointed to the primitive, often non-existent surveillance of the interface between human and animal diseases. But the mythology of bold, preemptive (and cheap) intervention against avian flu has been invaluable to the cause of rich countries, like the US and UK, who prefer to invest in their own biological Maginot lines rather than dramatically increasing aid to epidemic frontlines overseas, as well as to big pharma, which has battled developing-world demands for the generic, public manufacture of critical antivirals like Roche’s Tamiflu.

Click here for the rest of this article.